Is BPC-157 with KPV legal in the United Kingdom?

Two peptides sold together for gut complaints, most commonly 10 mg of each in a 20 mg vial. The combination has never been studied. One half has five small human studies by routes nobody uses, the other half has no human data of any kind, and the vial is injected while the claim is about the gut.

This is the most coherent blend in the vendor catalogue on paper, which is why it is worth being careful about. BPC-157 came out of gastric juice research and its animal literature is largely gastrointestinal.

Mechanism: KPV blocks NF-kB and MAP kinase signalling in intestinal epithelial and immune cells, which is the mechanism behind its mouse colitis results. BPC-157 acts through angiogenic and cytoprotective pathways described on its own page and shows gastrointestinal protection in rodent models.

Regulatory history: Not approved and never evaluated as a combination. BPC-157 alone was reviewed by FDA staff for the July 2026 Pharmacy Compounding Advisory Committee, which found no adequate human data.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for BPC-157 with KPV at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.